Quiet Vector LLC Home Added by user manually
Menu
Request a confidential conversation

Independent MedTech technical due diligence that exposes material engineering, regulatory, cybersecurity, verification, and execution risk before close.

Findings are translated into integration cost, regulatory timeline impact, and return sensitivity so investors and operators can commit with clearer risk-adjusted conviction.

Request a confidential conversation

Key Questions Assessed in MedTech Technical Due Diligence

The engagement answers four questions the investment committee needs answered but rarely receives with the clarity these questions deserve:

  1. Is the target's engineering foundation structurally sound, or does it carry hidden material risk that would surface only after investment?
  2. Is the regulatory submission defensible under actual FDA or Notified Body scrutiny, or is it constructed from artifacts that would not survive a rigorous observation?
  3. What is the realistic execution timeline and cost to close identified gaps — and is that timeline consistent with the investment thesis and the post-close integration plan?
  4. Does the engineering organization have the talent, depth, and institutional sustainability to execute the development plan — or does the program depend on individuals whose departure would create a knowledge gap that cannot be closed quickly?

This output surfaces material engineering and regulatory risk in terms investment decision-makers can use immediately.

Evaluation Framework

What is evaluated

Seven diligence domains used to identify regulator-readiness strength, execution risk, and integration exposure in MedTech software and system programs.

  1. Domain 1 — Product Architecture and Design Controls

    Review of system and software architecture decisions in the context of design control execution, including requirement decomposition, trace structure, and whether architectural intent is consistently carried through documented development artifacts.

  2. Domain 2 — Regulatory Evidence Quality

    Assessment of the quality, coherence, and audit-readiness of regulatory evidence packages, with focus on whether documentation is complete, internally consistent, and defensible under external review.

  3. Domain 3 — V&V Evidence Strength

    Analysis of verification and validation evidence strength, including protocol rigor, pass/fail clarity, anomaly disposition, and objective demonstration that safety- and performance-critical claims are supported.

  4. Domain 4 — Execution Maturity

    Determination of how reliably the organization executes under quality and schedule pressure, including planning realism, decision control, cross-functional handoff quality, and the repeatability of regulator-ready delivery.

  5. Domain 5 — Cybersecurity Posture

    Evaluation of cybersecurity maturity relative to medical device expectations, including threat-informed design controls, security requirements traceability, vulnerability handling practices, and evidence of implementation discipline.

  6. Domain 6 — Engineering Talent and Organizational Sustainability

    Assessment of engineering team composition, key-person concentration risk, and long-term sustainability of technical output. This evaluates whether regulator-ready practices persist post-close or degrade when institutional knowledge departs, assessed through document review, authorship and sign-off traceability, and structured leadership interviews. Findings are expressed as concentration and sustainability risk, not a personnel or HR review.

  7. Domain 7 — Hardware-Software Interface

    Evaluation of hardware-software boundary control, including interface definition and verification, control logic traceability, and fault handling, as well as cybersecurity at the hardware-software interface for connected or network-adjacent devices. This assesses design control integrity and integration depth, not PCB layout, signal integrity, or component selection engineering.

What You Receive

The engagement concludes with a structured diligence report prepared for the investment committee. The report is written to be read by both engineering stakeholders and non-engineering decision-makers — the diligence lead, the attorney, the CFO, and the partner making the investment recommendation.

Engineering Assessment Summary

An executive-level evaluation of the target's engineering maturity. This section answers the question the investment committee needs answered before it reviews the detailed findings: does the target's engineering foundation hold, or does it carry material risk that must be priced into the deal structure? The summary is structured for clarity and speed — it does not repeat the full report. It is the document that shapes the committee's understanding of what the full report contains and what the findings mean for the investment decision.

Risk-Rated Findings

Each identified gap, weakness, or area of concern is assigned a risk rating and a characterization of the effort required to close it. The rating distinguishes between items that represent material investment risk — gaps that would affect post-close integration cost, regulatory timeline, or investment return — and items that are manageable within normal post-close integration. Each finding includes a remediation-orientation estimate: what is needed to close the gap, at what level of effort, and what that means for the timeline and cost structure of the post-close integration plan. Findings are grounded in specific documents, test results, architecture artifacts, and process records — not in general impressions.

Remediation Roadmap

A prioritized plan for closing identified gaps. The roadmap distinguishes between items that require action before the investment closes and items that can be addressed during post-close integration. The priority ranking is based on the risk rating, the regulatory exposure of the gap, and the investment thesis implications — not on the order in which the gaps were discovered. The roadmap is structured so that the diligence team, the legal team, and the integration planning team can each use it for their respective purposes without requiring a separate interpretation.

Delivery and Debrief

The full report is delivered in draft form for internal review, followed by a final version. A debrief call with the diligence team is included to walk through the findings, clarify any technical items, and answer follow-up questions. All work is governed by a standard NDA. The diligence report is marked confidential and is delivered only to the hiring party.

Domain depth

Device classes, standards fluency, and evaluation coverage

Device types and regulatory pathways

Class II and Class III medical devices. Active implantable devices. Life-critical and life-sustaining systems. 510(k), De Novo, and PMA pathways. U.S. FDA and EU MDR regulatory programs.

Standards and frameworks

ISO 14971 (risk management) · ISO 13485 (quality management) · IEC 62304 (software lifecycle) · IEC 62366 (usability engineering) · IEC 60601 (electrical safety) · IEC 81001-5-1 (healthcare cybersecurity) · ANSI/AAMI SW96:2023 (software lifecycle and cybersecurity) · IEC 62443 (industrial cybersecurity) · IEC 82304 (health software) · AAMI TIR57 (threat modeling for medical device cybersecurity) · FDA premarket cybersecurity guidance

Evaluation domains

Product architecture and design controls · Regulatory evidence quality · Cybersecurity risk management and threat modeling · V&V evidence strength · Execution maturity and quality system integration · Engineering talent and organizational sustainability · Hardware-software interface and control logic design risk · Traceability across requirements, hazards, controls, and verification.

What determines post-close outcomes

The investment committee's blind spot is rarely financial. It is engineering — and it is organizational. Financial diligence teams are good at modeling revenue, assessing market opportunity, and structuring deal terms. Engineering diligence is the step most likely to be either skipped entirely or performed at a level insufficient to surface the material risks that determine post-close integration cost, regulatory timeline, and investment return. This engagement fills both gaps. Independent, senior, and grounded in what the actual evidence shows — not what the target's management claims about their program.

The assessment is performed by one senior engineer with 35+ years in Class II and Class III active devices, not assembled from a team of generalists. The findings reflect a single accountable judgment. That is deliberate: a diligence report written by four people who each saw one quarter of the evidence cannot state whether the whole thing holds together.

Request a confidential conversation about a device program or target review.

A short intake call clarifies scope. I tell you honestly whether I can help — and if I cannot, I say so.

— Wayne Larson, Principal Engineer, Quiet Vector LLC

Contact

Location
Minnesota, USA
Phone
612-860-8507
Email
[email protected]

Thank you — your message was sent.

Something went wrong. Please try again.

Concise details help prioritize response and scope.